消息动态
当前位置: 首页 » 最新资讯 » 消息动态  
“糖尿病治疗策略研究”创下多个中国之最

中国科学院和国家自然科学基金委员会共同主办的中国知名学术期刊SCIENCE CHINA Life Sciences(《中国科学:生命科学》英文版)2017年第3期,发表了迄今为止中国2型糖尿病领域规模最大的IV期随机对照临床研究--中国糖尿病治疗策略研究,证实了以“二甲双胍及西格列汀”为基础的二联和三联治疗方案兼具有效性和安全性


《中《中国科学:生命科学》英文版

该项目研究首席科学家长江学者特聘教授,中山大学附属第三医院,中山大学糖尿病研究所所长翁建平教授表示,策略研究根植中国,专为中国糖尿病患者“量身设计”。该研究结果将为广大医务工作者进一步探索提升糖尿病血糖控制达标水平的临床策略提供重要的本土数据,造福更多中国2型糖尿病患者。

翁建平教授在中国糖尿病治疗策略研究结果发表媒体发布会上解读研究结果。

SCIENCE CHINA Life Sciences, a scientific journal sponsored by the Chinese Academy of Sciences and the National Natural Science Foundation of China, published the findings of the largest type 2 diabetes phase IV randomized controlled clinical trial to date - the Study of China’s Diabetes Treatment (STRATEGY Study), in its third issue. The study shows that dual and triple therapy treatments based on a combination of Metformin and Sitagliptin are effective and safe.


嘉宾在中国糖尿病治疗策略研究结果发表媒体发布会上合影。

The lead scientist on the study Professor Jianping Weng, Chang Jiang Scholar Professor and Director of the Research Center for Diabetes Care at the Third Affiliated Hospital of Sun Yat-Sen University, said STRATEGY is a study conducted in China, for China, customized for diabetes sufferers in the country. The findings will provide invaluable domestic data to help medical professionals further explore clinical strategies to raise standards of care for keeping blood glucose levels under control, thereby benefiting more type 2 diabetes patients in China.


专为中国糖尿病患者“量身设计”


Customized study for Diabetes patients in China
中国是全球糖尿病患者人数最多的国家*,成年2型糖尿病患者约1.13亿,占全球糖尿病患者总数的1/4。但是,近2/3患者血糖控制未能达标。2型糖尿病是一种慢性进展性疾病,随着时间的延续,单药治疗往往很难达到持续降糖的作用。
*国际糖尿病联盟(IDF)糖尿病概览,2015,第7版。
China has the highest number of diabetes sufferers in the world. There are some 113 million adult patients with type 2 diabetes in China, making up nearly ¼ of the total globally; nearly 2/3 are unable to keep their blood glucose within safe levels. Type 2 diabetes is a chronic progressive disease - over time, relying solely on a single drug to lower blood glucose is rarely effective.



策略研究创下多个“中国之最”


STRATEGY creates many firsts in China
2012年8月,策略研究正式启动。该研究由中华医学会和中山大学支持,中山大学附属第三医院牵头,默沙东中国赞助,创下多个“中国记录”:

STRATEGY started officially in August 2012. The study is supported by the Chinese Medical Association(CMA) and Sun Yat-Sen University, with the Third Affiliated Hospital of Sun Yat-Sen University at the lead and MSD China as sponsor. It has created a number of records in China:



“中国糖尿病治疗策略研究”主要结果

Key Findings of the STRATEGY Study

让科研成果在中国的土地上开花结果

Letting the Study Findings take root and blossom in China

《中国科学:生命科学》常务副主编昌增益教授在会上强调:“去年,国家领导人在全国科技创新大会上提出,‘广大科技工作者要把论文写在祖国的大地上,把科技成果应用在实现现代化的伟大事业中’。令人欣喜的是,以中国糖尿病策略研究为代表的中国本土创新研究成果,正越来越多地发表在中国本土学术期刊上,展示了中国的科研成果,同时也对提高本土期刊的影响力起到了重要的推动作用。”

《中国科学:生命科学》常务副主编昌增益教授在中国糖尿病治疗策略研究结果发表媒体发布会上发言。

此外,此次策略研究是一次学会、科研院校、医院和企业四方合作的典型默沙东联合中华医学会和中山大学附属第三医院为参与策略研究的中心提供了良好的学习和交流平台。默沙东中国表示:公司将积极投身国家“健康中国2030”战略,推进糖尿病防控策略的实施,帮助更多患者得到更好的治疗,实现健康生活。

Professor Zengyi Chang, Deputy Editor-in-chief of SCIENCE CHINA Life Sciences stressed, “The majority of researchers in science and technology should author their papers in their motherland, and use the fruit of their research to advance the great cause of modernization, as President Xi Jinping has requested. It is gladdening to see groundbreaking scientific research  as represented by the STRATEGY study, increasingly being published in Chinese scientific journals, displaying China’s scientific spirit as well as boosting the influence of local scientific journals.
STRATEGY is also a model for four-way collaboration between medical associations, research institutions, hospitals, and corporations MSD China, together with the Chinese Medical Association and the Third Affiliated Hospital of Sun Yat-Sen University provided an excellent platform for learning and exchange for all the institutions involved in the STRATEGY study. MSD China said the company will continue take the initiative to contribute to Healthy China 2030, advancing diabetes prevention and control to help more patients get better treatment and live healthier lives.

返回
地址:广州市黄埔大道西601号暨南大学第二文科楼十层
邮编:510632
电话:020-85223261
Address: 10/F The 2nd Social Sciences Building, Jinan
University, 601 Huangpu Road West, Guangzhou, 510632, P.R.China
Tel: 020-85223261